Difference between revisions of "Team:BGU Israel"

 
Line 143: Line 143:
 
   <table>
 
   <table>
 
<tr>
 
<tr>
−
         <td><div class="checklist" >
+
         <td style="border-style: hidden;"><div class="checklist" >
 
           <div class="medal">
 
           <div class="medal">
 
               <a href="https://2015.igem.org/Team:BGU_Israel/Achievements">
 
               <a href="https://2015.igem.org/Team:BGU_Israel/Achievements">
Line 149: Line 149:
 
               </a>  
 
               </a>  
 
           </div></div></td>
 
           </div></div></td>
−
          <td>   
+
        </tr></table>
−
          <center style="margin-top: 10px;">
+
−
          <div id="clustrmaps-widget"></div><script type="text/javascript">  var _clustrmaps = { 'url': 'https://2015.igem.org/Team:BGU_Israel', 'user': 1176746, 'server': '3', 'id': 'clustrmaps-widget', 'version': 1, 'date': '2015-08-19', 'lang': 'en', 'corners': 'square' }; (function () { var s = document.createElement('script'); s.type = 'text/javascript'; s.async = true; s.src = 'http://www3.clustrmaps.com/counter/map.js'; var x = document.getElementsByTagName('script')[0]; x.parentNode.insertBefore(s, x); })();</script><noscript><a href="http://www3.clustrmaps.com/user/9bc11f4aa" target="blank"><img src="http://www3.clustrmaps.com/stats/maps-no_clusters/2015.igem.org-Team-BGU_Israel-thumb.jpg" alt="Locations of visitors to this page" /></a></noscript>
+
−
            </center>
+
−
          </td></tr></table>
+
 
<br /><br />
 
<br /><br />
 
<!-- finish HERE ----------------------------------------------------------------------------------------------->
 
<!-- finish HERE ----------------------------------------------------------------------------------------------->

Latest revision as of 16:02, 18 September 2015

Team:BGU Israel
Achievements
Project description
Design
Results
Practices and Polices

The Boomerang system: synthetic machine for cancer therapy

Despite recent treatment advancements, cancer is still a major cause of mortality worldwide. One of the fundamental problems preventing the development of effective therapy is the difficulty to target cancer cells exclusively.
In Boomerang, we're engineering a genetic device based on a simple concept of AND logic gate: the activation of our CRISPR/Cas9-based system is dependent on the existence of two cancer-specific promoters that control the expression of Cas9 and gRNA, and the combination of these two will occur only in cancer cells. CRISPR/Cas9 system allows several applications of Boomerang: 1) disruption of genes essential for cancer survival; and 2) activation of suicide genes, or color proteins for cancer cell detection (e.g., for complete surgical removal).
Our system can be potentially designed according to unique characteristics of a patient's tumor, paving the way to personalized medicine. We hope that our strategy will change the approach to cancer treatments.